Device Start-Ups Reap More Corporate Venture
This article was originally published in Start Up
Corporate VCs are increasingly becoming a stable supplier of capital to medical device companies. Corporate investors have been participating in a growing percentage of deals being done, according to Elsevier’s Strategic Transactions, and remain focused on later-stage rounds.
You may also be interested in...
Device start-ups raised $1.7 billion in 2013, and approximately 75% of the total was from Series C or later rounds, a sign that investors are still more comfortable making investments in more advanced companies.
Corporate venture investment is seen as increasingly important in life sciences finance. Plus news on recent financings by Retrophin, Sophiris Bio, Regado Biosciences and Tigercat Pharma.
Despite the dire headlines, VCs are still investing in medtech start-ups, although the deals are becoming fewer and later stage. Start-ups looking for funding have to be more creative and look beyond traditional sources of funding, according to a discussion by six European venture capitalists speaking at the IN3 meeting in Dublin in April 2013.